The only once-daily oral preventive CGRP receptor antagonist1

Turn on quick and continuous migraine preventive power with QULIPTA

Across a 12-week clinical trial (QULIPTA 60 mg)*:

Month Icon

Significant 54% reduction in mean monthly migraine days vs 33% for placebo1,2

– Similar results were seen in the Phase 2b/3 Dose-finding Study

Reduction Icon

Quick migraine day reductions were observed Day 1 after the first dose, Week 1, and Month 13

Patient Icon

Over 60% of patients cut their migraine days by at least half vs 29% for placebo1

*Data from the Phase 3 ADVANCE trial.

*Data from the Phase 3 ADVANCE trial.

INDICATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily. 
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily. 
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

Please see full Prescribing Information.

References

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION

QULIPTA™ (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily. 
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily. 
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

Please see full Prescribing Information.